多西他赛每周给药联合奥沙利铂二线治疗晚期非小细胞肺癌

Effect of weekly administration of docetaxel combined with oxaliplatin on non-small cell lung cancer

目的观察多西他赛每周给药联合奥沙利铂二线治疗晚期非小细胞肺癌（NSCLC）的近期疗效和毒性反应。方法 38例一线化疗进展的晚期NSCLC患者予多西他赛35mg/m2静滴1h,d1、d8;奥沙利铂130mg/m2,d1,21天为1周期。至少治疗2个周期。结果 38例患者中,完全缓解（CR）2例,部分缓解（PR）12例,无变化（NC）16例,进展（PD）8例,总有效率（RR）为36.8%（14/38）,临床获益率为78.9%。毒副反应主要为骨髓抑制、消化道反应、脱发和外周神经毒性,大部分患者为1、2级反应,耐受良好。骨髓抑制为剂量限制性毒性,其中白细胞减少52.6%（20/38）,3~4级为10.5%（4/38）。非血液学毒副作用轻微,全部病例无治疗相关性死亡发生。结论多西他赛每周给药联合奥沙利铂方案治疗晚期NSCLC疗效好、毒副反应轻、耐受性好。

Objective To study the effect and toxicity of weekly docetaxel combined with oxaliplatin on non-small cell lung cancer（NSCLC）.Methods Thirty-eight patients with advanced NSCLC were enroled in this study.The patients received docetaxel 35 mg/m2 at day 1 and 8 followed by 1-week break.Oxaliplatin 130mg/m2 was administrated at day 1.One cycle consisted of 21 days and all patients received at least 2 cycles.Results Of the total 38 patients,two patients achieved CR,12 PR,16 NC,and 8 PD.The overall response rate was 36.8%（14/38）.The clinical beneficial ratio was 78.9%.The major toxicities were myelosuppression,nausea,vomiting,alopecia and peripheral neurotoxicity with the majority at grade Ⅰ or Ⅱ and were well tolerated.Myelosuppression was dose-limiting toxicity and leukopenia accounted for 52.6%,10.5% of myelo-suppression cases（4/38） were at grade Ⅲ to Ⅳ.The non-hematological toxicity was mild.There was no therapy-related death.Conclusion Weekly docetaxel administration combined with oxaliplatin is effective in the treatment of advanced NSCLC with mild to moderate toxicity and good tolerance.